Clearwater, FL, September 13, 2023 – dG Medical Group, with a dedication to providing patients, physicians, and clinicians the most advanced and beneficial technology, is launching research studies in the use of Mesenchymal Stem Cell (MSC) Exosomes for a variety of medical conditions. This landmark of an achievement makes it the only product legally permitted to be sold for clinical use through research.
Partnered with scientists and universities. dG Medical Group aims to revolutionize healthcare by leveraging the potential of regenerative medicine. Through interdisciplinary collaboration, research, and ethical innovation, advanced therapies are being tested that rejuvenate damaged tissues, restore organ function, and provide long-term solutions for patients with debilitating conditions.
Compared to stem cells, the exosome treatment that dG Medical Group has adopted is cell free, meaning it represents a low-risk treatment. “Studies have shown that treatments with exosomes show similar or better results when it comes to enhancing the body’s natural healing processes,” says President, Michael Major. “This is as compared to stem cell treatment. Based on the similar or better results shown with exosomes, it is thought that stem cell treatments achieve beneficial effects through the secretion of exosomes. After all the trials and testing, it is an amazing scientific advancement.”
Offering consistency, quality, and regulated products, dG Medical Group aims to provide healthcare workers with trusted products that align with valid, competent concentrations. They partner with local medical research institutions to perform innovative research on the regenerative properties of stem cell derived exosomes
“Our mission is to revolutionize healthcare,” says Major. “The research we do in collaboration with other medical research institutions has allowed us to leverage the current solutions we know of and build upon them. Mesenchymal stem cells (MSCs) are multipotent cell types, such as bone cells, cartilage cells, fat cells and muscle cells. Human umbilical cord MSCs are also a type of stem cell that possess immunomodulatory properties. This means that, among other things, they can regulate the immune response. We hope that, with these groundbreaking discoveries and research, that we can continue to improve quality of life, extend healthy lifespans, and contribute to a future where regenerative medicine is a cornerstone of healthcare.”
With this emerging field of medicine, regulatory authorities such as the FDA play a key role in ensuring the safety and efficacy of exosome-based therapies. As this new form of healthcare continues to be researched and improved upon, we may see an increase in this type of medicine used across the globe. The FDA has recently notified the industry that all regenerative medicine products intended for clinical use must go through their regulatory process, emphasizing how new and upcoming this form of healthcare is in the United States.
As dG Medical Group learned, MSCs are revered as a ground-breaking field of research and technology. dG hopes to continue acting as a trailblazer in the world of advanced regenerative healthcare.
About dG Medical Group
dG Medical Group is a healthcare product master distributor that sells Mesenchymal Stem Cell Exosomes for research purposes. Partnering with local medical research institutions, they continue to aid in the collection of data on the beneficial properties of mesenchymal stem cells and human umbilical cord mesenchymal stem cells.
SOURCE: dG Medical Group
To learn more about the rapidly evolving exosome market, view the “The Global Exosome Market – Market Size, Forecast, Trials and Trends, 2023.”
